Maine ranks 46th in lung cancer cases nationally

Nov.16.2022
Maine ranks 46th in lung cancer cases nationally
Maine's lung cancer rates rank 46th in the US in 2022, with lower survival rates than the national average. Early screening is encouraged.

According to data from the American Lung Association, the "State of Lung Cancer" report for 2022 shows that Maine ranks 46th in the country for its rate of new lung cancer cases.


The annual report released on Tuesday by the American Lung Association highlighted the number of deaths from lung cancer in Maine and examined key indicators, including new cases, survival rates, early diagnosis, surgical treatment, lack of treatment, and screening rates.


A report on the state of lung cancer nationwide has shown a continued increase in survival rates.


The five-year survival rate for lung cancer has increased by 21% from 2014 to 2018, reaching 25%.


In Maine, the American Lung Association has reported that lung cancer survival rates are 23.8% lower than the national average.


Lung cancer screening is crucial for early diagnosis, which can save lives. Unfortunately, in Maine, we have a higher incidence of lung cancer compared to other states and not enough people are receiving this life-saving screening," said Lance Boucher, Director of Public Relations for the American Lung Association in Maine. "We can all help alleviate the burden of lung cancer in Maine. If you are eligible for lung cancer screening, we encourage you to discuss this with your doctor. If you have family members who are eligible, please encourage them to get screened.


Currently, 14.2 million Americans meet the screening guidelines set forth by the US Preventive Services Task Force (USPSTF). According to these guidelines, the American Lung Association states that individuals between the ages of 50 to 80 with a smoking history of 20 pack-years (defined as smoking 1 pack per day for 20 years or 2 packs per day for 10 years) are eligible for lung cancer screening if they are current smokers or have quit within the past 15 years.


The report from the American Lung Association reveals Maine's ranking.


The incidence rate of lung cancer is 70.8 cases per 100,000 people, ranking 46th in the country. The national rate is 56.7 cases per 100,000 people. The survival rate of 23.8% ranks 25th in the country. The national five-year survival rate for lung cancer diagnosis is 25%, and the 25th early detection rate is 25.8%. Only 25.8% of cases are diagnosed in the early stages, which have higher survival rates, nationwide. The 11.8% lung cancer screening rate ranks fifth nationally. By conducting annual low-dose CT scans for high-risk individuals, lung cancer mortality can be reduced by up to 20%. Only 5.8% of high-risk individuals are screened nationally. Surgery ranks eighth nationally, accounting for 23.7%. Lung cancer can typically be treated with surgery if diagnosed early and has not spread. 20.8% of cases receive surgery nationwide. Lack of treatment ranks sixth nationally, accounting for 16.9%. Nationwide, 20.6% of cases do not receive treatment. The American Lung Association's "State of Lung Cancer" report emphasizes the need for Maine to take more action to reduce the burden of lung cancer and encourage everyone to join the effort to end lung cancer.


Declaration:


This article is compiled from third-party information and is intended solely for industry exchange and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the veracity and accuracy of the article's contents. The translation of this article is only for communication and research within the industry.


Due to limitations in translation abilities, this article's translation may not fully convey the same meaning as the original. Please refer to the original article for the most accurate information.


2FIRSTS maintains full alignment with the Chinese government's position and statements on any domestic issues, as well as issues involving Hong Kong, Macau, Taiwan, and foreign relations.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.